These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3698040)

  • 1. Trial of droperidol as an antiemetic in cisplatin chemotherapy.
    Kelley SL; Braun TJ; Meyer TJ; Rempel P; Pearlman NW
    Cancer Treat Rep; 1986 Apr; 70(4):469-72. PubMed ID: 3698040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy.
    Lewis GO; Bernath AM; Ellison NM; Gallagher JG; Porter PA; Rine KT
    Clin Pharm; 1984; 3(6):618-21. PubMed ID: 6391784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis.
    Owens NJ; Schauer AR; Nightingale CH; Golub GR; Martin RS; Williams HM; Schauer PK
    Clin Pharm; 1984; 3(2):167-70. PubMed ID: 6373102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?].
    Lehoczky O; Bagaméri A; Sárosi Z; Kulcsár T; Pulay T
    Orv Hetil; 2001 Aug; 142(31):1681-4. PubMed ID: 11556262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer].
    Wataba K; Sagae S; Fukunaka N; Sugimura M; Akutagawa N; Hayashi T; Yamana K; Nakamura T; Terasawa K; Mizumoto H; Kitajima Y; Kudo R
    Gan To Kagaku Ryoho; 1997 Apr; 24(6):691-7. PubMed ID: 9126306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study.
    Minegishi Y; Ohmatsu H; Miyamoto T; Niho S; Goto K; Kubota K; Kakinuma R; Kudoh S; Nishiwaki Y
    Eur J Cancer; 2004 May; 40(8):1188-92. PubMed ID: 15110882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
    Schmidinger M; Budinsky AC; Wenzel C; Piribauer M; Brix R; Kautzky M; Oder W; Locker GJ; Zielinski CC; Steger GG
    Wien Klin Wochenschr; 2000 Jul; 112(14):617-23. PubMed ID: 11008323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer.
    Hitt R; Hornedo J; Colomer R; Hidalgo M; Brandariz A; Peña M; Vicent JA; Cortés-Funes H
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-58-S2-64. PubMed ID: 9045339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis.
    Saller R; Hellenbrecht D
    Cancer Treat Rep; 1985 Nov; 69(11):1301-3. PubMed ID: 3912040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M; Kanzaki J
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1095-101. PubMed ID: 9239162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
    J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy].
    Hisano C; Nakano S; Okuma K; Masumoto N; Fujishima H; Nakamura M; Niho Y
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1175-81. PubMed ID: 8751806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin].
    Takahashi T; Mori K; Suga Y; Tominaga K
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1873-5. PubMed ID: 8397491
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
    Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
    J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
    Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.